A recent study showed that the administration of dupilumab was associated with comparable/significant improvement in signs and symptoms of atopic dermatitis in patients with or without comorbid asthma.
The proportion of participants in the treatment groups who achieved EASI-50 was statistically significant compared with placebo as early as 4 weeks after beginning treatment.
Researchers compared the efficacy of moisturizer containing 4-t-butylcyclohexanol and licochalcone A to 0.02% triamcinolone acetonide (TA) for treating facial dermatitis.
The efficacy and generally safe profile of upadacitinib supports advancing to a phase 3 trial.
Data from a preliminary placebo-controlled trial on ASN002 were presented at the 2018 American Academy of Dermatology Annual Meeting.
The safety and efficacy of PF-04965842 was evaluated in 375 individuals in a phase 3, randomized, double-blind, placebo-controlled trial.
Despite not reaching significance in the total population, the progressive clinical improvements seen in patients with severe AD suggest a therapeutic advantage.
Omalizumab, alone or in combination with a short-term course of corticosteroids, is highly effective for the treatment of refractory chronic spontaneous urticaria.
Twice-daily use of topical corticosteroids in all treatment arms, both prior to and during the study, impaired participants’ ability to fully assess the efficacy of lebrikizumab.
Although the step-care approach is the current standard of care, this approach is flawed in several ways with respect to achieving optimal outcomes.
